| 1 | 7507245 | STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. | Proc Natl Acad Sci U S A | 1994 Jan 18 |
1 |
| 2 | 7545021 | Expression and physiologic significance of Kit ligand and stem cell tyrosine kinase-1 receptor ligand in normal human CD34+, c-Kit+ marrow cells. | Blood | 1995 Sep 15 |
1 |
| 3 | 8352256 | Gentamicin clearance during hemodialysis: a comparison of high-efficiency cuprammonium rayon and conventional cellulose ester hemodialyzers. | Am J Kidney Dis | 1993 Aug |
1 |
| 4 | 8630382 | Induction of hematopoietic commitment and erythromyeloid differentiation in embryonal stem cells constitutively expressing c-myb. | Blood | 1996 Mar 15 |
1 |
| 5 | 8641368 | Effects of Flt3 ligand and interleukin-7 on in vitro growth of acute lymphoblastic leukemia cells. | Exp Hematol | 1996 Feb |
5 |
| 6 | 8744592 | Receptor-selective retinoid agonists and teratogenic activity. | Drug Metab Rev | 1996 Feb-May |
1 |
| 7 | 9276617 | Characterization of two different cytoplasmic protein tyrosine kinases from human breast cancer. | Carcinogenesis | 1997 Aug |
1 |
| 8 | 9529123 | FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. | Leukemia | 1998 Mar |
2 |
| 9 | 9669840 | Phenotypic and functional characterization of mobilized peripheral blood CD34+ cells coexpressing different levels of c-Kit. | Leuk Res | 1998 Apr |
3 |
| 10 | 9918857 | p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. | Biochem Biophys Res Commun | 1999 Jan 19 |
1 |
| 11 | 10080542 | Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. | J Leukoc Biol | 1999 Mar |
1 |
| 12 | 10089903 | Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized CD34+ hematopoietic progenitors: role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15. | Exp Hematol | 1999 Mar |
1 |
| 13 | 10340407 | Rapid ex vivo expansion of human umbilical cord hematopoietic progenitors using a novel culture system. | Exp Hematol | 1999 May |
1 |
| 14 | 10720129 | In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. | Leukemia | 2000 Mar |
1 |
| 15 | 11027663 | Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. | Biochem Biophys Res Commun | 2000 Oct 14 |
3 |
| 16 | 11090695 | Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine. | Int J Immunopharmacol | 2000 Nov |
1 |
| 17 | 11454991 | Flt-3 and its ligand are expressed in neural crest-derived tumors and promote survival and proliferation of their cell lines. | Lab Invest | 2001 Jul |
1 |
| 18 | 11455967 | Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. | Leukemia | 2001 Jul |
6 |
| 19 | 11468194 | A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. | Blood | 2001 Aug 1 |
1 |
| 20 | 11747761 | Effects of dexamethasone on Flt3 receptor expression and proliferation induced by recombinant human Flt3 ligand in malignant hematopoietic cells. | Acta Pharmacol Sin | 2001 Jun |
7 |
| 21 | 12010785 | A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. | Blood | 2002 Jun 1 |
3 |
| 22 | 12060632 | Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. | Clin Cancer Res | 2002 Jun |
1 |
| 23 | 12145694 | Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. | Leukemia | 2002 Aug |
1 |
| 24 | 12239146 | Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. | Blood | 2002 Oct 1 |
1 |
| 25 | 12239147 | Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. | Blood | 2002 Oct 1 |
1 |
| 26 | 12351406 | SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. | Blood | 2002 Oct 15 |
12 |
| 27 | 12357354 | Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. | Leukemia | 2002 Oct |
5 |
| 28 | 12393388 | Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. | Blood | 2002 Dec 15 |
1 |
| 29 | 12406902 | The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. | Blood | 2003 Feb 15 |
1 |
| 30 | 12435730 | A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. | J Biol Chem | 2003 Feb 14 |
2 |
| 31 | 12515727 | A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. | Blood | 2003 Apr 15 |
5 |
| 32 | 12529667 | Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. | Leukemia | 2003 Jan |
1 |
| 33 | 12531805 | SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. | Blood | 2003 May 1 |
8 |
| 34 | 12538485 | In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. | Clin Cancer Res | 2003 Jan |
1 |
| 35 | 12649163 | SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. | Blood | 2003 Aug 1 |
1 |
| 36 | 12673719 | Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. | Cancer | 2003 Apr 15 |
1 |
| 37 | 12707374 | Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. | J Mol Diagn | 2003 May |
1 |
| 38 | 12748309 | SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. | Mol Cancer Ther | 2003 May |
1 |
| 39 | 12796379 | Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. | Clin Cancer Res | 2003 Jun |
2 |
| 40 | 12815052 | Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). | J Biol Chem | 2003 Aug 29 |
10 |
| 41 | 12843001 | A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. | Blood | 2003 Oct 15 |
2 |
| 42 | 12854887 | Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. | Leuk Lymphoma | 2003 Jun |
1 |
| 43 | 14555522 | FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. | Clin Cancer Res | 2003 Oct 1 |
11 |
| 44 | 14578466 | Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. | Mol Cancer Ther | 2003 Oct |
1 |
| 45 | 14599092 | Epidemiology and clinical burden of acute myeloid leukemia. | Expert Rev Anticancer Ther | 2003 Oct |
1 |
| 46 | 14604974 | Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. | Blood | 2004 Mar 15 |
2 |
| 47 | 14654525 | An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. | Clin Cancer Res | 2003 Nov 15 |
5 |
| 48 | 14715630 | Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. | Blood | 2004 Jun 15 |
1 |
| 49 | 14726387 | Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. | Blood | 2004 May 15 |
2 |
| 50 | 14753710 | Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. | J Chromatogr A | 2004 Jan 23 |
1 |